GT Biopharma (GTBP)

Company Profile

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE™ technology.

Company profile

Ticker

GTBP

Exchange

NASDAQ

Website

www.gtbiopharma.com

CEO

Anthony Cataldo

Incorporated

Delaware

Location

California

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Abbott Laboratories • Teva- Pharmaceutical Industries • Bristol-Myers Squibb • Lilly(Eli) & Co • Viatris • Abbvie • Bausch Health Companies ...

Former names

OXIS INTERNATIONAL INC

SEC CIK

0000109657

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

941620407

GTBP stock data

1M 1Y 5Y

Analyst ratings and price targets

Last 3 months

Latest filings (excl ownership)

View all

8-K

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

28 Feb 23

8-K

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering

4 Jan 23

424B5

Prospectus supplement for primary offering

3 Jan 23

8-K

Departure of Directors or Certain Officers

13 Dec 22

8-K

Amendments to Articles of Incorporation or Bylaws

31 Oct 22

Notice of effectiveness

Correspondence with SEC

Transcripts

Earnings call transcript

2021 Q2

13 Aug 21

Latest ownership filings

View all

SC 13G

ARMISTICE CAPITAL, LLC

RAJESH C MD SHROTRIYA

RAJESH C MD SHROTRIYA

Financial summary

Financial statements Chart GTBP financial data

Quarter (USD)	Sep 22	Jun 22	Mar 22	Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	2.47 mm	2.47 mm	2.47 mm	2.47 mm	2.47 mm	2.47 mm
Cash burn (monthly)	964.33 k	601.42 k	2.34 mm	2.80 mm	972.67 k	1.22 mm
Cash used (since last report)	5.57 mm	3.48 mm	13.53 mm	16.21 mm	5.62 mm	7.04 mm
Cash remaining	-3.11 mm	-1.01 mm	-11.07 mm	-13.75 mm	-3.16 mm	-4.58 mm
Runway (months of cash)	-3.2	-1.7	-4.7	-4.9	-3.2	-3.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q4 2022

GTBP institutional ownership history Ownership history

20.3% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	36	33	+9.1%
Opened positions	11	2	+450.0%
Closed positions	8	17	-52.9%
Increased positions	9	6	+50.0%
Reduced positions	5	15	-66.7%

13F shares	Current	Prev Q	Change
Total value	5.12 bn	125.84 mm	+3968.2%
Total shares	6.61 mm	2.64 mm	+150.3%
Total puts	0.00	0.00
Total calls	0.00	0.00
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Armistice Capital	3.39 mm	$3.00 bn	NEW
Vanguard	1.13 mm	$998.54 mm	+0.0%
BLK Blackrock	372.79 k	$330.18 mm	+0.3%
RY Royal Bank Of Canada	281.96 k	$250.00 mm	+13534.3%
Alpha Capital Anstalt	265.23 k	$809.00 k	0.0%
Geode Capital Management	223.44 k	$199.00 k	-0.2%
Baskin Financial Services	151.35 k	$134.00 k	NEW
Millennium Management	131.91 k	$118.00 k	-14.3%
WFC Wells Fargo & Co.	100.56 k	$89.07 mm	+18317.6%
BK Bank Of New York Mellon	95.24 k	$84.35 mm	0.0%

Largest transactions	Shares	Bought/sold	Change
Armistice Capital	3.39 mm	+3.39 mm	NEW
RY Royal Bank Of Canada	281.96 k	+279.89 k	+13534.3%
Baskin Financial Services	151.35 k	+151.35 k	NEW
WFC Wells Fargo & Co.	100.56 k	+100.01 k	+18317.6%
STT State Street	81.88 k	+81.88 k	NEW
Renaissance Technologies	46.20 k	+46.20 k	NEW
Virtu Financial	0.00	-24.86 k	EXIT
Millennium Management	131.91 k	-22.07 k	-14.3%
Jane Street	53.92 k	+21.20 k	+64.8%
Occudo Quantitative Strategies	0.00	-17.54 k	EXIT

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

GTBP insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
27 Jan 23	Wendel Bruce	Option to purchase Common Stock Common Stock	Grant	Acquire A	No	No	0.837	500,000	418.50 k	500,000
27 Jan 23	Manu Ohri	Option to purchase Common Stock Common Stock	Grant	Acquire A	No	No	0.837	500,000	418.50 k	500,000
27 Jan 23	Michael Martin Breen	Option to purchase Common Stock Common Stock	Grant	Acquire A	No	No	0.837	500,000	418.50 k	500,000
27 Jan 23	Shrotriya Rajesh C MD	Option to purchase Common Stock Common Stock	Grant	Acquire A	No	No	0.837	500,000	418.50 k	500,000
15 Jul 22	Wendel Bruce	Option to purchase Common Stock Common Stock	Grant	Acquire A	No	No	2.48	50,000	124.00 k	50,000
15 Jul 22	Wendel Bruce	Option to purchase Common Stock Common Stock	Grant	Acquire A	No	No	2.48	50,000	124.00 k	50,000